Barclays raised its price target but kept its Neutral rating. The report gives no new information about Insulet's sales or products, so it does not change the company's outlook.
That change reflects Barclays' revised view of Insulet's shares, not new sales, product, or profit information. Keeping the rating at Neutral gives no clear reason to change the company's outlook.
Follow Insulet Corporation (PODD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PODD